Inactive Instrument

Fennec Pharmaceuticals Inc Stock price Other OTC

Equities

CA31447P1009

Biotechnology & Medical Research

Sales 2023 21.25M Sales 2024 * 49.19M Capitalization 300M
Net income 2023 -16M Net income 2024 * 6M EV / Sales 2023 14.3 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 6.09 x
P/E ratio 2023
-18.7 x
P/E ratio 2024 *
49.8 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 82.34%
More Fundamentals * Assessed data
Dynamic Chart
Wedbush on Fennec's Q4 MT
Transcript : Fennec Pharmaceuticals Inc., 2023 Earnings Call, Mar 21, 2024
Fennec Pharmaceuticals up 3.2% in US Premarket, Reports Narrower Q4 Loss of $0.10 Per Share MT
Fennec Pharmaceuticals Brief: Cited Pro forma fourth quarter cash in excess of US$55 million MT
Fennec Pharmaceuticals Brief: Achieved PEDMARK Full-Year 2023 Net Product Sales of US$21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 MT
North American Morning Briefing : Investors -2- DJ
Fennec Pharmaceuticals Brief: Net losses for the fourth quarter and year ended December 31, 2023, of US$2.7 million ($0.10 per share) and $16.0 million ($0.60 per share), respectively MT
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Wedbush on Fennec's Deal for Pedmarqsi in EU MT
Sector Update: Health Care Stocks Steady Premarket Monday MT
Sector Update: Health Care MT
Fennec Pharmaceuticals, Norgine in Exclusive Licensing Agreement to Commercialize Pedmarqsi in Europe, Australia, and NZ MT
Fennec Pharmaceuticals Brief: Fennec Pharmaceuticals and Norgine Over the Weekend Entered into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand MT
Fennec Pharmaceuticals Signs Exclusive Licensing Deal With Norgine MT
More news

Latest transcript on Fennec Pharmaceuticals Inc

Managers TitleAgeSince
Chief Executive Officer 48 09-07-06
Director of Finance/CFO 49 09-07-06
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 70 11-08-24
Chairman 67 14-04-24
Director of Finance/CFO 49 09-07-06
More insiders
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company, which is focused on its product candidate PEDMARK. The Company sells its product through a field force, including regional pediatric oncology specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration (FDA) approved therapy indicates to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic and solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.
Related indices
More about the company
  1. Stock
  2. Equities
  3. Stock Fennec Pharmaceuticals Inc.
  4. Stock Fennec Pharmaceuticals Inc - Other OTC